Tech Company Financing Transactions
Expedition Therapeutics Funding Round
Expedition Therapeutics closed a $115 million Series B funding round on 8/5/2026. Investors included General Atlantic, Adage Capital Management and Balyasny Asset Management.
Transaction Overview
Company Name
Announced On
8/5/2026
Transaction Type
Venture Equity
Amount
$115,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support advancement of its lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development, expand its pipeline of new therapies for inflammatory diseases, and further enhance its research discovery.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2261 Market Street 10321
San Francisco, CA 94114
USA
San Francisco, CA 94114
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
At Expedition Therapeutics, we believe that disease-controlling treatments that address fundamental disease mechanisms should be the new standard for chronic obstructive pulmonary disease (COPD). Our therapy is designed to target neutrophilic inflammation, a novel and clinically validated pathway that is a major driver of tissue damage, airway remodeling, and progressive decline in lung function. Our lead candidate, EXPD-101, is a potent, oral, once-daily DPP1 inhibitor being developed for COPD, with the potential to deliver continuing improvement for millions of patients who currently have no disease-controlling treatment options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Yi Larson
Chief Medical Officer
Geoff Gilmartin
VP - Bus. Development
Eric Hu
Browse more venture capital transactions:
Prev: 8/5/2026: Mironid venture capital transaction
Next: 8/5/2026: Pathos AI venture capital transaction
Share this article
Where The Data Comes From
We document funding rounds that are announced publicly. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs